Dyno Therapeutics launches two new AAV Capsids, AI platform for rare disease therapeutic development: Watertown, Massachusetts Saturday, May 16, 2026, 13:00 Hrs [IST] Dyno Therape ...

Dyno Therapeutics launches two new AAV capsids and AI platform for rare disease therapeutic development at ASGCT 2026 ...

Regenxbio said its experimental gene therapy for Duchenne muscular dystrophy succeeded in a trial, paving the way for a ...

Detailed price information for Satellos Bioscience Inc (MSCL-T) from The Globe and Mail including charting and trades.

Four patients with LGMD-R5 (gamma-sarcoglycanopathy, formerly LGMD-2C) have received the ATA-200 gene therapy as part of the ongoing Phase 1b/2 trial evaluating the safety, pharmacodynamics, and ...

Standing calf exercises after 55 that improve balance, ankle strength, and walking stability without equipment.

REGENXBIO Inc. (Nasdaq: RGNX) announced positive topline and interim functional data from the pivotal Phase III portion of ...

Running and cycling both create powerful lower bodies, but experts say they strengthen the legs in completely different ways.

VY1706 IND application process on track for Q2 2026; clinical entry expected H2 2026 -- Data from eight ASGCT presentations ...

Treatment for a rare muscle-wasting condition for a nine-year-old has "fundamentally changed the course of his life", his ...

Regenxbio announces positive results from pivotal phase III AFFINITY DUCHENNE study of RGX-202 to treat Duchenne muscular dystrophy: Rockville, Maryland Friday, May 15, 2026, 14:0 ...

New preclinical data show PBGENE-DMD drove up to a 3x higher dystrophin protein restoration in skeletal muscle and up to 12x higher in respiratory muscle in early-juvenile mice compared to ...